Pluvicto

Generic name: Lutetium Lu 177 Vipivotide Tetraxetan
Dosage form: injection, for intravenous use
Drug class: Therapeutic radiopharmaceuticals

Usage of Pluvicto

Pluvicto is a targeted radiopharmaceutical treatment for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body.

Pluvicto is used in patients who have already been treated with other anti-cancer treatments.

Patients will need a scan before receiving Pluvicto, using Locametz or another approved PSMA-11 imaging agent to identify the PSMA-positive lesions.

Pluvicto side effects

Pluvicto may cause serious side effects including:

Myelosuppression. Contact your healthcare provider if you experience any signs or symptoms of myelosuppression, such as tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty to stop bleeding, or frequent infections with signs, such as fever, chills, sore throat or mouth ulcers.

Renal Toxicity. Contact your healthcare provider if you experience any signs or symptoms of renal toxicity such as passing urine less often than usual or passing much smaller amounts of urine than usual.

Common side effects may include:

fatigue

dry mouth

nausea

anemia

decreased appetite

constipation.

Before taking Pluvicto

You should not receive Pluvicto if you are allergic to lutetium Lu 177 vipivotide tetraxetan.

Relate drugs

How to use Pluvicto

Usual Adult Dosage for Prostate Cancer

- 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses.

- Use: treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

Warnings

Pluvicto may cause harm to an unborn baby.

Men with female partners should use effective contraception for intercourse during treatment with Pluvicto, and for 14 weeks after the last dose.

Pluvicto may cause temporary or permanent infertility in males.

Pluvicto contributes to your overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer.

To minimize radiation exposure to others after you receive Pluvicto

you should limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days

you should refrain from sexual activity for 7 days

you should sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, and from pregnant women for 15 days.

Pluvicto can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia, and neutropenia.

Pluvicto can cause severe renal toxicity. You should remain well hydrated and urinate frequently before and after administration of Pluvicto to prevent kidney injury. You will receive kidney function tests before and during your treatment.

What other drugs will affect Pluvicto

Pluvicto is not thought to interact with other medicines.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.